1
|
Demols A, Borbath I, Van den Eynde M, Houbiers G, Peeters M, Marechal R, Delaunoit T, Goemine JC, Laurent S, Holbrechts S, Paesmans M, Van Laethem JL. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol 2020; 31:1169-1177. [PMID: 32464280 DOI: 10.1016/j.annonc.2020.05.018] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 05/06/2020] [Accepted: 05/07/2020] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies. PATIENTS AND METHODS REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase II study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic biliary tract cancer that progressed after gemcitabine/platinum chemotherapy. Patients were randomly assigned 1 : 1 to best supportive care plus either regorafenib 160 mg once daily 3 weeks on/1 week off or placebo until progression or unacceptable toxicity. No crossover was allowed. The primary objective was progression-free survival (PFS). Secondary objectives were response rate, overall survival, and translational analysis. RESULTS Sixty-six patients with intrahepatic (n = 42), perihilar (n = 6), or extrahepatic (n = 9) cholangiocarcinoma, or gallbladder carcinoma (n = 9) were randomized, 33 to each treatment group (33 per group). At a median follow-up of 24 months, all patients had progressed and six patients were alive. Median treatment duration was 11.0 weeks [95% confidence interval (CI): 6.0-15.9] in the regorafenib group and 6.3 weeks (95% CI: 3.9-7.0) in the placebo group (P = 0.002). Fourteen of 33 patients (42%) in the regorafenib group had a dose reduction. Stable disease rates were 74% (95% CI: 59-90) in the regorafenib group and 34% with placebo (95% CI: 18-51; P = 0.002). Median PFS in the regorafenib group was 3.0 months (95% CI: 2.3-4.9) and 1.5 months (95% CI: 1.2-2.0) in the placebo group (hazard ratio 0.49; 95% CI: 0.29-0.81; P = 0.004) and median overall survival was 5.3 months (95% CI: 2.7-10.5) and 5.1 months (95% CI: 3.0-6.4), respectively (P = 0.28). There were no unexpected/new safety signals. CONCLUSION Regorafenib significantly improved PFS and tumor control in patients with previously treated metastatic/unresectable biliary tract cancer in the second- or third-line setting. CLINICAL TRIAL REGISTRATION The trial is registered in the European Clinical Trials Register database (EudraCT 2012-005626-30) and at ClinicalTrials.gov (NCT02162914).
Collapse
Affiliation(s)
- A Demols
- GE and Digestive Oncology Department, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
| | - I Borbath
- GE Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - M Van den Eynde
- GE Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - G Houbiers
- Oncology Department, Saint-Joseph Community Health Center, Liège, Belgium
| | - M Peeters
- Oncology Department - University Hospital Antwerp, Edegem, Belgium
| | - R Marechal
- GE and Digestive Oncology Department, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| | - T Delaunoit
- GE Department, INDC Entité Jolimontoise, Haine-St-Paul, Belgium
| | - J-C Goemine
- Oncology Department, Cliniques et Maternité Ste Elisabeth, Namur, Belgium
| | - S Laurent
- GE Department - Ghent University Hospital, Ghent, Belgium
| | - S Holbrechts
- Oncology Department, Centre Hospitalier Universitaire A. Paré, Mons, Belgium
| | - M Paesmans
- Data Center, Institut J. Bordet, Brussels, Belgium
| | - J-L Van Laethem
- GE and Digestive Oncology Department, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
2
|
Demols A, Borbath I, Van den Eynde M, Houbiers G, Peeters M, Marechal R, Delaunoit T, Goeminne J, Laurent S, Holbrechts S, Paesmans M, Van Laethem J. Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A. Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget 2018; 9:17756-17769. [PMID: 29707145 PMCID: PMC5915153 DOI: 10.18632/oncotarget.24879] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Accepted: 03/01/2018] [Indexed: 12/18/2022] Open
Abstract
Predictive biomarkers are eagerly awaited in advanced colorectal cancer (aCRC). Targeted sequencing performed on tumor and baseline plasma samples in 20 patients with aCRC treated with regorafenib identified 89 tumor-specific mutations of which ≥50% are also present in baseline plasma. Droplet digital PCR (ddPCR) assays were optimized to monitor circulating tumor DNA (ctDNA) levels in plasmatic samples collected throughout the treatment course and showed the importance of using the absolute value for ctDNA rather than the mutant/wild type ratio in monitoring the therapy outcome. High baseline cell free DNA (cfDNA) levels are associated with shorter overall survival (OS) (HR 7.38, P=0.001). An early increase (D14) in mutated copies/mL is associated with a significantly worse PFS (HR 6.12, P=0.008) and OS (HR 8.02, P=0.004). These data suggest a high prognostic value for early ctDNA level changes and support the use of blood-born genomic markers as a tool for treatment.
Collapse
Affiliation(s)
- Caroline Vandeputte
- Gastro Intestinal Oncology Unit, Medical Oncology, Institut Jules Bordet, Brussels, Belgium
| | - Pashalina Kehagias
- Gastro Intestinal Oncology Unit, Medical Oncology, Institut Jules Bordet, Brussels, Belgium
| | - Hakim El Housni
- Department of Medical Genetics, Hôpital Erasme-ULB, Brussels, Belgium
| | - Lieveke Ameye
- Data Centre, Institut Jules Bordet, Brussels, Belgium
| | | | - Christine Desmedt
- Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Christos Sotiriou
- Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Amélie Deleporte
- Gastro Intestinal Oncology Unit, Medical Oncology, Institut Jules Bordet, Brussels, Belgium
| | - Francesco Puleo
- Gastro Intestinal Oncology Unit, Medical Oncology, Institut Jules Bordet, Brussels, Belgium
| | - Karen Geboes
- Service of Digestive Oncology, Universitair Ziekenhuis Gent, Gent, Belgium
| | | | - Gauthier Demolin
- Gastroenterology Department, Centre Hospitalier Chrétien St-Joseph, Liège, Belgium
| | - Marc Peeters
- Oncology Department, Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium
| | - Lionel D'Hondt
- Oncology Department, Centre Hospitalier Universitaire, UCL Namur (site de Godinne), Dinant, Belgium
| | - Jos Janssens
- Department of Gastroenterology, AZ Turnhout, Turnhout, Belgium
| | - Javier Carrasco
- Oncology Department, Grand Hôpital de Charleroi, Charleroi, Belgium
| | - Raphaël Marechal
- Department of Gastroenterology, GI Cancer Unit, ULB-Erasme, Brussels, Belgium
| | - Maria Gomez Galdon
- Department of Pathology, Jules Bordet Institute, Free University of Brussels, Brussels, Belgium
| | - Pierre Heimann
- Department of Medical Genetics, Hôpital Erasme-ULB, Brussels, Belgium
| | | | - Patrick Flamen
- Nucleair Medicine Imaging and Therapy Department, Institut Jules Bordet, Brussels, Belgium
| | - Alain Hendlisz
- Gastro Intestinal Oncology Unit, Medical Oncology, Institut Jules Bordet, Brussels, Belgium
| |
Collapse
|
4
|
Demols A, Marechal R, van Laethem J. Regorafenib in Locally Advanced and Metastatic Intrahepatic or Hilar Cholangiocarcinoma: a Randomized Double-Blinded Phase Ii Trial. Reach In. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Deleporte A, Hendlisz A, Delaunoit T, Marechal R, Peeters M, Holbrechts S, van den Eynde M, Houbiers G, Moreau M, Flamen P. Somore Trial: Combining Sorafenib (SOR) with Capecitabine (CAP) Yields Highly Encouraging Survival Results and Elevated Metabolic Response Rate in Chemorefractory Metastatic Colorectal Cancer (MCRC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33180-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
6
|
Hendlisz A, Marechal R, Durbecq V, Rouas G, Larsimont D, Kains J, Van Laethem J. Modulation and prognostic value of epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) during chemotherapy (CT) in patients with metastatic colorectal cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Marechal R. Improper selection of study end-point may mislead statistical results. Surgery 2008; 143:298; author reply 299. [PMID: 18242348 DOI: 10.1016/j.surg.2007.08.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2007] [Accepted: 08/18/2007] [Indexed: 11/28/2022]
|
8
|
|
9
|
Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481-5. [PMID: 16434988 PMCID: PMC2361170 DOI: 10.1038/sj.bjc.6602966] [Citation(s) in RCA: 102] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2005] [Revised: 12/19/2005] [Accepted: 12/21/2005] [Indexed: 12/31/2022] Open
Abstract
Gemcitabine and oxaliplatin (GEMOX) are active as first-line therapy against advanced pancreatic cancer. This study aims to evaluate the activity and tolerability of this combination in patients refractory to standard gemcitabine (GEM). A total of 33 patients (median age of 57) were included with locally advanced and metastatic evaluable diseases, who had progressed during or following GEM therapy. The GEMOX regimen consisted of 1000 mg m(-2) of GEM at a 100-min infusion on day 1, followed on day 2 by 100 mg m(-2) of oxaliplatin at a 2-h infusion; a cycle that was given every 2 weeks. All patients received at least one cycle of GEMOX (median 5; range 1-29). Response by 31 evaluable patients was as follows: PR: 7/31(22.6%), s.d. > or = 8 weeks: 11/31(35.5%), s.d. < 8 weeks: 1/31(3.2%), PD: 12/31(38.7%). Median duration of response and TTP were 4.5 and 4.2 months, respectively. Median survival was 6 months (range 0.5-21). Clinical benefit response was observed in 17/31 patients (54.8%). Grade III/IV non-neurologic toxicities occurred in 12/33 patients (36.3%), and grade I, II, and III neuropathy in 17(51%), 3(9%), and 4(12%) patients, respectively. GEMOX is a well-tolerated, active regimen that may provide a benefit to patients with advanced pancreatic cancer after progression following standard gemcitabine treatment.
Collapse
Affiliation(s)
- A Demols
- 1Department of Gastroenterology, GI Oncology Unit, Erasme University Hospital, Route de Lennik 808, Brussels 1070, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Van Laethem JL, Polus M, Marechal R, Demols A, Gay F, Marijken M, Hendlisz A, Peeters M. Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J.-L. Van Laethem
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| | - M. Polus
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| | - R. Marechal
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| | - A. Demols
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| | - F. Gay
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| | - M. Marijken
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| | - A. Hendlisz
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| | - M. Peeters
- Erasme University Hospital, Brussels, Belgium; CHU Sart Tilman, Liege, Belgium; Universitair Ziekenhuis, Ghent, Belgium; Bordet Institute, Brussels, Belgium
| |
Collapse
|
11
|
Taccone FS, Marechal R, Meuleman N, Aoun M. Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: a case report. Support Care Cancer 2003; 11:742-4. [PMID: 13680323 DOI: 10.1007/s00520-003-0522-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2003] [Accepted: 07/23/2003] [Indexed: 10/26/2022]
Abstract
A 47-year-old man with acute lymphocytic leukemia was admitted in intensive care unit (ICU) because of respiratory failure. He had febrile neutropenia and probable invasive pulmonary aspergillosis (IA). Amphotericin B renal toxicity and clinical deterioration prompted a shift to caspofungin and resulted in a successful response.
Collapse
Affiliation(s)
- F S Taccone
- Intensive Care Unit (ASTI), Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | |
Collapse
|
12
|
Abstract
We investigated possible immunological changes in 15 professional football players before, during and after the sports season. We studied the leucocyte count as well as different functions such as T-lymphocyte proliferation, NK activity, chemotaxis and phagocytosis of neutrophils. Training and competitions did not produce any change in the total number of leucocytes but increased neutrophil counts and decreased T4 lymphocyte counts. We also observed a slight decrease of T-lymphocyte proliferation and a significant decrease of neutrophil functions. On the other hand, training and competitions did not induce significant changes in the number of NK cells nor in the total NK cytotoxic activity. The different change observed tended to normalize after the sports season. Our results suggest a predominant neutrophil function depression in football players during a training season which could partly explain the susceptibility of elite athletes to infections.
Collapse
Affiliation(s)
- T Bury
- Department of Pneumology, CHU Sart Tilman, Liege, Belgium
| | | | | | | |
Collapse
|
13
|
Moens L, Roos P, De Rudder J, Hoste J, De Paepe P, Van Hende J, Marechal R, Waelkens M. White marble from Italy and Turkey: An archaeometric study based on minor-and trace-element analysis and petrography. J Radioanal Nucl Chem 1988. [DOI: 10.1007/bf02036401] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Lukoki L, Marechal R, Otoul E. Les ancetres sauvages des haricots cultives: Vigna radiata (L.) Wilczek et V. mungo (L.) Hepper. ACTA ACUST UNITED AC 1980. [DOI: 10.2307/3667837] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
15
|
Marechal R, Baudet JC. Transfert du genre africain Kerstingiella Harms a Macrotyloma (Wight & Arn.) Verdc. (Papilionaceae). ACTA ACUST UNITED AC 1977. [DOI: 10.2307/3667980] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
16
|
Brahy R, Lejeune G, Marechal R, Carlier A, Alexandre G. [Hemodynamic study of the hypothenar eminence under conditions of permeability or obstruction of the cubital artery]. Acta Orthop Belg 1977; 43:233-40. [PMID: 930577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
17
|
Baudet JC, Marechal R. Signification taxonomique de la presence de poils uncinules chez certains genres de Phaseoleae et d'Hedysareae (Papilionaceae). ACTA ACUST UNITED AC 1976. [DOI: 10.2307/3667726] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
18
|
Marechal R. [New osteoclast]. Ann Otolaryngol Chir Cervicofac 1974; 91:537-8. [PMID: 4469768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
19
|
Pirnay F, Marechal R, Dujardin R, Lamy M, Deroanne R, Petit JM. Exercise during hyperoxia and hyperbaric oxygenation. Int Z Angew Physiol 1973; 31:259-68. [PMID: 4741646 DOI: 10.1007/bf00693711] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
20
|
Hamoir G, Marechal R, Bassleer R. Electron spin resonance spectra of white, cardiac and various red skeletal muscles of the carp, Cyprinus carpio L. Experientia 1973; 29:25-6. [PMID: 4354054 DOI: 10.1007/bf01913229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
21
|
Pirnay F, Marechal R, Radermecker R, Petit JM. Muscle blood flow during submaximum and maximum exercise on a bicycle ergometer. J Appl Physiol (1985) 1972; 32:210-2. [PMID: 5007872 DOI: 10.1152/jappl.1972.32.2.210] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
22
|
Dirnay F, Radermecker R, Marechal R, Petit JM. M�sure du d�bit sanguin musculaire � l'aide du X�non 133 pendant l'exercice musculaire. Eur J Appl Physiol 1972. [DOI: 10.1007/bf00704173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Marechal R. Donnees cytologiques sur les especes de la sous-tribu des Papilionaceae - Phaseoleae - Phaseolinae. Deuxieme serie. ACTA ACUST UNITED AC 1970. [DOI: 10.2307/3667577] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Marechal R. Donnees cytologiques sur les especes de la sous-tribu des Papilionaceae - Phaseoleae - Phaseolinae Premiere serie. ACTA ACUST UNITED AC 1969. [DOI: 10.2307/3667695] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
25
|
Marechal R, Otoul E. Contribution a l'etude cytotaxonomique des Papilionaceae-Phaseoleae-Phaseolinae. III: Comparaison des chromosomes somatiques de trois especes de Dolichos Lam. ACTA ACUST UNITED AC 1966. [DOI: 10.2307/3667193] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|